Novartis | NVS | Long at $99.00
As one of the largest pharmaceutical companies in the world, Novartis 
NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be poised for another move up. However, entry into the lower $90's or even $80's is still not off the table and, in my view, a great opportunity. Thus, at $99.00, NVS is in a personal buy zone.
Target #1 = $110.00
Target #2 = $120.00
NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be poised for another move up. However, entry into the lower $90's or even $80's is still not off the table and, in my view, a great opportunity. Thus, at $99.00, NVS is in a personal buy zone.Target #1 = $110.00
Target #2 = $120.00
Trade active
Target #1 reached for a 11.1% gain.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.